Letter to the Editor Open Access
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Mar 15, 2023; 14(3): 343-346
Published online Mar 15, 2023. doi: 10.4239/wjd.v14.i3.343
Ca2+/cAMP ratio: An inflammatory index for diabetes, hypertension, and COVID-19
Leandro Bergantin, Department of Pharmacology, Universidade Federal de São Paulo, São Paulo 04039-032, Brazil
ORCID number: Leandro Bergantin (0000-0001-7432-9958).
Author contributions: Bergantin LB is the sole author.
Conflict-of-interest statement: There are no conflicts of interest to report.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Leandro Bergantin, PhD, Professor, Department of Pharmacology, Universidade Federal de São Paulo, Rua Pedro de Toledo, 669 Vila Clementino, São Paulo 04039-032, Brazil. leanbio39@yahoo.com.br
Received: November 13, 2022
Peer-review started: November 13, 2022
First decision: December 1, 2022
Revised: December 11, 2022
Accepted: February 8, 2023
Article in press: February 8, 2023
Published online: March 15, 2023

Abstract

Ca2+/cAMP ratio could serve as an inflammatory index for diseases like hyp-ertension, diabetes, and coronavirus disease 2019.

Key Words: Ca2+/cAMP ratio, COVID-19, Inflammatory index, Diabetes

Core Tip: Ca2+/cAMP ratio could serve as an inflammatory index for diseases like hypertension, diabetes, and coronavirus disease 2019.



TO THE EDITOR

There is a clear relationship between Ca2+ signaling, e.g., increased Ca2+ signals, and inflammatory responses[1,2]. Considering the cumulative data from the scientific literature, including data of high evidence such as meta-analysis and systematic reviews, we can now link Ca2+ dyshomeostasis as an upstream factor for hypertension, diabetes, and other inflammatory processes[1,2]. In fact, severe inflammatory outcomes are described to be linked to a critical coronavirus disease 2019 (COVID-19) result[1,3]. Intriguingly, some reports have also observed an increased severity of COVID-19 in patients with diabetes[1,3]. To assess this issue, a meta-analysis[3] was performed by conducting a literature review of Scopus, PubMed, Science Direct, and Web of Science. Observational studies, case-reports, and case-series reports that analyzed diabetes in COVID-19 patients were included in this meta-analysis[3]. The authors concluded that diabetes is a risk factor and plays a role in the disease severity and in the mortality of individuals with COVID-19. In fact, a bidirectional relationship between COVID-19 and diabetes has been established[4]. Recent data have shown that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can produce a direct damage to the pancreas that could worsen hyperglycemia, and even cause the onset of diabetes in previously non-diabetic subjects[4]. Like diabetes, hypertension has also been recognized as a prevalent cardiovascular comorbidity in patients with COVID-19[5]. It is well established that hypertension increases the severity of SARS-CoV-2–infected patients[5]. In addition, obesity is a well-known risk factor for metabolic syndrome (MetS), hypertension, and diabetes. Recent reports revealed that it is also a vital risk factor for COVID-19, as demonstrated by a recent phenome-wide analysis of COVID-19[6].

Moreover, a link between infection with viruses and Ca2+ dyshomeostasis is well-discussed, e.g., altering host cellular processes in the benefit of the viruses[7-10]. Thus, Ca2+ dyshomeostasis induced by viruses may trigger an alteration of the host cellular system that benefits virus survival and could serve as a link for an increased severity of COVID-19 in patients with diabetes[1,3].

An interesting longitudinal study also evaluated the relationship between serum Ca2+ levels and the incidence of MetS, diabetes, and hypertension[11]. This study[11] was performed through cross-sectional and longitudinal analyses (period 2010–2016). Logistic regression was used for cross-sectional analysis of the association between serum Ca2+ levels or albumin-corrected calcium (ACCA) and the prevalence of MetS, diabetes, or hypertension. Receiver operating characteristic curve analysis was applied for calculating an optimal cut-off value of serum Ca2+ levels and ACCA[11]. Cox proportional regression analysis for the development of MetS, diabetes, and hypertension according to different cut-off values of serum Ca2+ levels and ACCA was performed. At baseline, there were 27364 participants in this study[11]. The authors[11] concluded that higher serum Ca2+ levels were associated with an increased risk of MetS, diabetes, and hypertension. A hypothesis which could link hypertension and higher serum Ca2+ levels postulates that the influx of Ca2+ into the smooth muscle of the arteries could lead to muscle contracture, then increasing vascular resistance and, therefore, could result in the development of hypertension[11]. Our previous reports[1,2,12-15] also discussed this issue. In fact, we postulated that dysregulation of Ca2+ signaling is linked to a sympathetic hyperactivity, then leading to hypertension[1,12,16]. In addition, a hypothesis which could link diabetes and higher serum Ca2+ levels postulates that serum Ca2+ is associated with insulin resistance in adipocytes and skeletal muscle[17,18]. Our previous reports are in accordance with this hypothesis[1,12,15]. In fact, whereas a physiological increase in the cytoplasmic concentration of Ca2+ is a significant trigger for releasing insulin, an abnormal elevation of Ca2+ could stimulate β-cell apoptosis, then decreasing insulin levels, contributing to diabetes[1,15].

Furthermore, reports of our group undoubtedly established that a rise of the concentration of cAMP can stimulate a Ca2+ release from the endoplasmic reticulum, entitled as Ca2+/cAMP signaling interaction[1,2,12-15]. In fact, a rise of the concentration of Ca2+ can markedly cause a decrease of the concentration of cAMP because of the negative feedback (Ca2+/cAMP signaling interaction). Thus, a disruption of this interaction can be linked with disorders, e.g., hypertension, diabetes, and COVID-19[1,2,15]. Although the interaction between these disorders may be linked with continued increases of the concentration of Ca2+, whether these increases could disturb Ca2+/cAMP signaling interaction needs more studies, e.g., in animal models and clinical trials. Indeed, previous studies corroborate this concept. For instance, in patients with diabetes, plasma concentrations of cAMP were significantly lower than those of normal subjects[19]. In addition, cAMP contents of platelets were measured and observed to be lower in hypertensive than in normotensive subjects[20]. Figure 1 summarizes previous discussion.

Figure 1
Figure 1 Altered Ca2+/cAMP ratio resulting from an inflammatory stimulus and infection with SARS-CoV-2. Altered Ca2+/cAMP ratio stimulates uncontrolled inflammation, leading to virus replication, increase of β-cell apoptosis and decrease of insulin levels, and sympathetic hyperactivity. Up/down arrows: Increase/decrease; COVID-19: Coronavirus disease 2019.

In conclusion, Ca2+/cAMP ratio could serve as an inflammatory index for diseases like hypertension, diabetes, and COVID-19[21,22].

Footnotes

Provenance and peer review: Invited article; Externally peer reviewed.

Peer-review model: Single blind

Specialty type: Endocrinology and metabolism

Country/Territory of origin: Brazil

Peer-review report’s scientific quality classification

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): E

P-Reviewer: Leowattana W, Thailand; Liao Z, Singapore; Zhang FQ, China S-Editor: Chen YL L-Editor: Wang TQ P-Editor: Chen YL

References
1.  Bergantin LB. Diabetes and inflammatory diseases: An overview from the perspective of Ca(2+)/3'-5'-cyclic adenosine monophosphate signaling. World J Diabetes. 2021;12:767-779.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in CrossRef: 11]  [Cited by in F6Publishing: 9]  [Article Influence: 3.0]  [Reference Citation Analysis (3)]
2.  Bergantin LB. A Timeline of Ca(2+)/cAMP Signalling: From Basic Research to Potential Therapeutics for Dementia. Curr Alzheimer Res. 2022;19:179-187.  [PubMed]  [DOI]  [Cited in This Article: ]  [Reference Citation Analysis (0)]
3.  Abdi A, Jalilian M, Sarbarzeh PA, Vlaisavljevic Z. Diabetes and COVID-19: A systematic review on the current evidences. Diabetes Res Clin Pract. 2020;166:108347.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 149]  [Cited by in F6Publishing: 121]  [Article Influence: 30.3]  [Reference Citation Analysis (1)]
4.  Lima-Martínez MM, Carrera Boada C, Madera-Silva MD, Marín W, Contreras M. COVID-19 and diabetes: A bidirectional relationship. Clin Investig Arterioscler. 2021;33:151-157.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 20]  [Cited by in F6Publishing: 49]  [Article Influence: 12.3]  [Reference Citation Analysis (0)]
5.  Peng M, He J, Xue Y, Yang X, Liu S, Gong Z. Role of Hypertension on the Severity of COVID-19: A Review. J Cardiovasc Pharmacol. 2021;78:e648-e655.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 41]  [Cited by in F6Publishing: 35]  [Article Influence: 11.7]  [Reference Citation Analysis (0)]
6.  Baranova A, Cao H, Teng S, Zhang F. A phenome-wide investigation of risk factors for severe COVID-19. J Med Virol. 2023;95:e28264.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 3]  [Cited by in F6Publishing: 18]  [Article Influence: 18.0]  [Reference Citation Analysis (0)]
7.  Olivier M. Modulation of host cell intracellular Ca2+. Parasitol Today. 1996;12:145-150.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 38]  [Cited by in F6Publishing: 37]  [Article Influence: 1.9]  [Reference Citation Analysis (0)]
8.  Nugent KM, Shanley JD. Verapamil inhibits influenza A virus replication. Arch Virol. 1984;81:163-170.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 44]  [Cited by in F6Publishing: 40]  [Article Influence: 1.0]  [Reference Citation Analysis (0)]
9.  Dionicio CL, Peña F, Constantino-Jonapa LA, Vazquez C, Yocupicio-Monroy M, Rosales R, Zambrano JL, Ruiz MC, Del Angel RM, Ludert JE. Dengue virus induced changes in Ca(2+) homeostasis in human hepatic cells that favor the viral replicative cycle. Virus Res. 2018;245:17-28.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 19]  [Cited by in F6Publishing: 21]  [Article Influence: 3.0]  [Reference Citation Analysis (0)]
10.  Scherbik SV, Brinton MA. Virus-induced Ca2+ influx extends survival of west nile virus-infected cells. J Virol. 2010;84:8721-8731.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 60]  [Cited by in F6Publishing: 63]  [Article Influence: 4.5]  [Reference Citation Analysis (0)]
11.  Chou CW, Fang WH, Chen YY, Wang CC, Kao TW, Wu CJ, Chen WL. Association between Serum Calcium and Risk of Cardiometabolic Disease among Community-dwelling Adults in Taiwan. Sci Rep. 2020;10:3192.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 8]  [Cited by in F6Publishing: 11]  [Article Influence: 2.8]  [Reference Citation Analysis (0)]
12.  Bergantin LB. Hypertension, Diabetes and Neurodegenerative Diseases: Is there a Clinical Link through the Ca2+/cAMP Signalling Interaction? Curr Hypertens Rev. 2019;15:32-39.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 15]  [Cited by in F6Publishing: 15]  [Article Influence: 3.0]  [Reference Citation Analysis (0)]
13.  Caricati-Neto A, García AG, Bergantin LB. Pharmacological implications of the Ca(2+)/cAMP signaling interaction: from risk for antihypertensive therapy to potential beneficial for neurological and psychiatric disorders. Pharmacol Res Perspect. 2015;3:e00181.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 24]  [Cited by in F6Publishing: 24]  [Article Influence: 2.7]  [Reference Citation Analysis (1)]
14.  Bergantin LB. The Interactions among Hypertension, Cancer, and COVID-19: Perspective with Regard to Ca(2+)/cAMP Signalling. Curr Cancer Drug Targets. 2022;22:351-360.  [PubMed]  [DOI]  [Cited in This Article: ]  [Reference Citation Analysis (0)]
15.  Bergantin LB. Debating the "bidirectional link" between diabetes and depression through the Ca(2+)/cAMP signalling: Off-label effects of Ca(2+) channel blockers. Pharmacol Res. 2019;141:298-302.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 16]  [Cited by in F6Publishing: 16]  [Article Influence: 3.2]  [Reference Citation Analysis (0)]
16.  Miranda-Ferreira R, de Pascual R, de Diego AM, Caricati-Neto A, Gandía L, Jurkiewicz A, García AG. Single-vesicle catecholamine release has greater quantal content and faster kinetics in chromaffin cells from hypertensive, as compared with normotensive, rats. J Pharmacol Exp Ther. 2008;324:685-693.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 26]  [Cited by in F6Publishing: 27]  [Article Influence: 1.6]  [Reference Citation Analysis (0)]
17.  Rooney MR, Pankow JS, Sibley SD, Selvin E, Reis JP, Michos ED, Lutsey PL. Serum calcium and incident type 2 diabetes: the Atherosclerosis Risk in Communities (ARIC) study. Am J Clin Nutr. 2016;104:1023-1029.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 37]  [Cited by in F6Publishing: 38]  [Article Influence: 4.8]  [Reference Citation Analysis (0)]
18.  Begum N, Leitner W, Reusch JE, Sussman KE, Draznin B. GLUT-4 phosphorylation and its intrinsic activity. Mechanism of Ca(2+)-induced inhibition of insulin-stimulated glucose transport. J Biol Chem. 1993;268:3352-3356.  [PubMed]  [DOI]  [Cited in This Article: ]
19.  Goldberg ML, Bohannon NV, Brooks RM, Tsalikian E, Lorenzi M, Forsham PH. Plasma cyclic nucleotide levels in juvenile-onset diabetes. Diabetes. 1977;26:936-943.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 4]  [Cited by in F6Publishing: 3]  [Article Influence: 0.1]  [Reference Citation Analysis (3)]
20.  Mazeaud MM, Le Quan Sang KH, Devynck MA. Platelet cyclic AMP in essential hypertension. J Hypertens. 1989;7:501-506.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 4]  [Cited by in F6Publishing: 6]  [Article Influence: 0.2]  [Reference Citation Analysis (0)]
21.  Bergantin LB. COVID-19 and Obesity: Reevaluating the Relationship Through Ca(2+)/cAMP Signalling. Curr Drug Res Rev. 2022;14:157-159.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1]  [Cited by in F6Publishing: 1]  [Article Influence: 0.5]  [Reference Citation Analysis (0)]
22.  Bergantin LB. Mental Disorders and Poor COVID-19 Prognosis: Reevaluating the Relationship through Ca(2+)/cAMP Signalling. Curr Top Med Chem. 2022;22:1215-1218.  [PubMed]  [DOI]  [Cited in This Article: ]  [Reference Citation Analysis (0)]